Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will examine the effectiveness of group metacognitive therapy in comparison with group meditation therapy, in patients with Generalised Anxiety Disorder. Individuals will be randomly assigned to either meditation or metacognitive therapy and undergo 8 group therapy sessions of their respective treatment condition.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metacognitive Therapy | Experimental | Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes. |
|
| Mindfulness Meditation Therapy | Experimental | Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Group Metacognitive Therapy | Behavioral |
|
| |
| Mindfulness Meditation Therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Hospital Anxiety and Depression Scale (HADS) | Administered at pre treatment, mid treatment, post treatment, and 6 month follow up |
| Measure | Description | Time Frame |
|---|---|---|
| CAS-I | Administered at pre treatment, mid treatment, post treatment, and 6 month follow up | |
| GAD-7 | Completed prior to week 1 of treatment.This will be administered prior to treatment as a screening measure for levels of anxiety. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lora Capobianco | University of Manchester | Principal Investigator |
| James Thompson | University of Manchester | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Rawnsley Building, Manchester Royal Infirmary, Oxford Road | Manchester | Lancashire | M23 9LT | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D000098647 | Generalized Anxiety Disorder |
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C009907 | 2-methylcyclopentadienyl manganese tricarbonyl |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Behavioral |
|
|
| PHQ-9 | Completed prior to week 1 of treatment.This will be administered prior to treatment as a screening measure for levels of depression. |